Top Banner
16

labma.uii.ac.id · 2020. 9. 4. · stroke (AIS). It reduces the efficacy or thromboIYSiS. increases infarct size. and worsens clinical outcome¶ Insulin-based therapies have generally

Jan 23, 2021

Download

Documents

dariahiddleston
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: labma.uii.ac.id · 2020. 9. 4. · stroke (AIS). It reduces the efficacy or thromboIYSiS. increases infarct size. and worsens clinical outcome¶ Insulin-based therapies have generally
Page 2: labma.uii.ac.id · 2020. 9. 4. · stroke (AIS). It reduces the efficacy or thromboIYSiS. increases infarct size. and worsens clinical outcome¶ Insulin-based therapies have generally
Page 3: labma.uii.ac.id · 2020. 9. 4. · stroke (AIS). It reduces the efficacy or thromboIYSiS. increases infarct size. and worsens clinical outcome¶ Insulin-based therapies have generally
Page 4: labma.uii.ac.id · 2020. 9. 4. · stroke (AIS). It reduces the efficacy or thromboIYSiS. increases infarct size. and worsens clinical outcome¶ Insulin-based therapies have generally
Page 5: labma.uii.ac.id · 2020. 9. 4. · stroke (AIS). It reduces the efficacy or thromboIYSiS. increases infarct size. and worsens clinical outcome¶ Insulin-based therapies have generally
Page 6: labma.uii.ac.id · 2020. 9. 4. · stroke (AIS). It reduces the efficacy or thromboIYSiS. increases infarct size. and worsens clinical outcome¶ Insulin-based therapies have generally
Page 7: labma.uii.ac.id · 2020. 9. 4. · stroke (AIS). It reduces the efficacy or thromboIYSiS. increases infarct size. and worsens clinical outcome¶ Insulin-based therapies have generally
Page 8: labma.uii.ac.id · 2020. 9. 4. · stroke (AIS). It reduces the efficacy or thromboIYSiS. increases infarct size. and worsens clinical outcome¶ Insulin-based therapies have generally
Page 9: labma.uii.ac.id · 2020. 9. 4. · stroke (AIS). It reduces the efficacy or thromboIYSiS. increases infarct size. and worsens clinical outcome¶ Insulin-based therapies have generally
Page 10: labma.uii.ac.id · 2020. 9. 4. · stroke (AIS). It reduces the efficacy or thromboIYSiS. increases infarct size. and worsens clinical outcome¶ Insulin-based therapies have generally
Page 11: labma.uii.ac.id · 2020. 9. 4. · stroke (AIS). It reduces the efficacy or thromboIYSiS. increases infarct size. and worsens clinical outcome¶ Insulin-based therapies have generally
Page 12: labma.uii.ac.id · 2020. 9. 4. · stroke (AIS). It reduces the efficacy or thromboIYSiS. increases infarct size. and worsens clinical outcome¶ Insulin-based therapies have generally
Page 13: labma.uii.ac.id · 2020. 9. 4. · stroke (AIS). It reduces the efficacy or thromboIYSiS. increases infarct size. and worsens clinical outcome¶ Insulin-based therapies have generally
Page 14: labma.uii.ac.id · 2020. 9. 4. · stroke (AIS). It reduces the efficacy or thromboIYSiS. increases infarct size. and worsens clinical outcome¶ Insulin-based therapies have generally
Page 15: labma.uii.ac.id · 2020. 9. 4. · stroke (AIS). It reduces the efficacy or thromboIYSiS. increases infarct size. and worsens clinical outcome¶ Insulin-based therapies have generally
Page 16: labma.uii.ac.id · 2020. 9. 4. · stroke (AIS). It reduces the efficacy or thromboIYSiS. increases infarct size. and worsens clinical outcome¶ Insulin-based therapies have generally